MCID: AVN001
MIFTS: 53

Avian Influenza malady

Categories: Respiratory diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Avian Influenza

About this section
Sources:
2CDC, 11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 38MedlinePlus, 39MeSH, 54Orphanet, 62SNOMED-CT, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Avian Influenza:

Name: Avian Influenza 11 54 2 13
Bird Flu 11 38 2
 
Influenza in Birds 39 68
Avian Flu 11

Characteristics:

Orphanet epidemiological data:

54
avian influenza:
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology11 DOID:4492
ICD1030 J09.X
MeSH39 D005585
SNOMED-CT62 55604004
Orphanet54 ORPHA454836
ICD10 via Orphanet31 J09

Summaries for Avian Influenza

About this section
MedlinePlus:38 Birds, just like people, get the flu. bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. most bird flu viruses can only infect other birds. however, bird flu can pose health risks to people. the first case of a bird flu virus infecting a person directly, h5n1, was in hong kong in 1997. since then, the bird flu virus has spread to birds in countries in asia, africa, the middle east, and europe. human infection is still very rare, but the virus that causes the infection in birds might change, or mutate, to more easily infect humans. this could lead to a pandemic, a worldwide outbreak of the illness. during an outbreak of bird flu, people who have contact with infected birds can become sick. it may also be possible to catch bird flu by eating poultry or eggs that are not well cooked or through contact with a person who has it. bird flu can make people very sick or even cause death. antiviral medicines may make the illness less severe, and may help prevent the flu in people who were exposed to it. there is currently no vaccine.

MalaCards based summary: Avian Influenza, also known as bird flu, is related to influenza and newcastle disease, and has symptoms including fever, cough and sore throat. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways are NGF processing and Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics. Affiliated tissues include respiratory tract of humans, testes and lung, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and digestive/alimentary.

Disease Ontology:11 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

Wikipedia:71 Avian influenza — known informally as avian flu or bird flu — refers to \"influenza caused by... more...

Related Diseases for Avian Influenza

About this section

Diseases related to Avian Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 51)
idRelated DiseaseScoreTop Affiliating Genes
1influenza11.1
2newcastle disease10.5
3humeroradioulnar synostosis10.5DDX58, NEU1
4steatorrhea10.2CXCL10, TNF
5angiodysplasia of intestine10.2CXCL10, DDX58
6atypical depressive disorder10.2CXCL10, TNF
7polycystic echinococcosis10.1HAS1, TNF
8swine influenza10.0
9severe acute respiratory syndrome10.0
10scleral disease10.0SFTPD, TNF
11laryngotracheitis9.9
12bronchitis9.9
13esophagus squamous cell papilloma9.9CXCL10, DDX58, SCRIB, TNF
14vaccinia9.9
15stomatitis9.9
16aleutian mink disease9.8DDX58, IFNA1, NEU1
17hemometra9.8IFNA1, TNF
18pneumonia9.8
19conjunctivitis9.8
20monkeypox9.8
21smallpox9.8
22idiopathic central precocious puberty9.6IFNA1, TNF
23babesiosis9.6DDX58, IFNA1, TNF
24malaria9.6
25west nile virus9.6
26adult respiratory distress syndrome9.6
27alopecia9.6
28meningoencephalitis9.6
29japanese encephalitis9.6
30respiratory failure9.6
31chlamydia9.6
32tetanus9.6
33rift valley fever9.6
34cholera9.6
35cryptosporidiosis9.6
36tularemia9.6
37leptospirosis9.6
38duodenitis9.6
39encephalitis9.6
40acute respiratory distress syndrome9.6
41hemorrhagic fever9.6
42myelitis9.6CXCL10, IFNA1, TNF
43whipple disease9.6DDX58, IRF7, TNF
44nervous system disease9.5DDX58, IFNA1, STAT2
45lichen nitidus9.5DDX58, IFNA1, TNF
46optic nerve disease9.4DDX58, IFNA1, IRF7, TNF
47hereditary ataxia9.4DDX58, IFNA1, IRF7, TNF
48intracranial hemorrhage in brain cerebrovascular malformations9.4CXCL10, IFNA1, IRF7, TNF
49multiple sclerosis, disease progression, modifier of9.3CXCL10, IFNA1, TNF
50taylor's syndrome9.0CXCL10, DDX58, HAS1, IFNA1, TNF

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to avian influenza

Symptoms & Phenotypes for Avian Influenza

About this section

Symptoms:

 11 (show all 10)
  • fever
  • cough
  • sore throat
  • muscle aches
  • nausea
  • diarrhea
  • vomiting
  • neurologic changes
  • pneumonia
  • acute respiratory distress

UMLS symptoms related to Avian Influenza:


snoring, pruritus, coughing

GenomeRNAi Phenotypes related to Avian Influenza according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-358.7CXCL10, FURIN, IFNA1, TMPRSS13

MGI Mouse Phenotypes related to Avian Influenza according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.6CRK, DDX58, FURIN, PCSK5, PCSK6, SCRIB
2MP:00053888.4CRK, NEU1, PCSK5, PCSK6, SCRIB, SFTPD
3MP:00053878.2CXCL10, DDX58, FURIN, IRF7, NEU1, PCSK5
4MP:00053978.2CXCL10, DDX58, FURIN, IRF7, NEU1, PCSK5
5MP:00107687.2CRK, CXCL10, DDX58, FURIN, NEU1, PCSK5

Drugs & Therapeutics for Avian Influenza

About this section

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 4, Phase 2, Phase 3, Phase 16428
2
Aluminum hydroxideapprovedPhase 2, Phase 3, Phase 120121645-51-2
Synonyms:
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
 
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
3
OseltamivirapprovedPhase 2, Phase 3, Phase 1101204255-11-8, 196618-13-065028
Synonyms:
(-)-oseltamivir
(3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid
(−)-oseltamivir
196618-13-0
204255-11-8
4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
AC1L22FK
AC1Q63H0
Agucort
Agucort (TN)
BIDD:GT0426
BRD-K76011241-045-01-5
C08092
CHEBI:7798
CHEMBL1229
CID65028
D08306
DB00198
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate
FT-0082384
 
GS 4104
GS-4104
GS4104
HMS2090C11
HSDB 7433
LS-57422
MolPort-005-933-026
NCGC00178698-01
Oseltamivir
Oseltamivir (INN)
Oseltamivir [INN:BAN]
Oseltamivir phosphate
Oseltamivirum
Ro-64-0796
Ro-640796
Tamiflu (*Phosphate salt 1:1*)
Tamiflu-Free
Tamvir
UNII-20O93L6F9H
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
oseltamivir
oseltamivirum
oséltamivir
4
Formaldehydeapproved, vet_approvedPhase 2, Phase 3, Phase 18450-00-0712
Synonyms:
Aldeide formica
Fannoform
Formaldehyde
Formalin
Formalina
Formaline
Formalith
Formic aldehyde
Formol
 
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde
5HemagglutininsPhase 3, Phase 1, Phase 2118
6Heptavalent Pneumococcal Conjugate VaccinePhase 3454
7Antiviral AgentsPhase 2, Phase 3, Phase 19732
8LaxativesPhase 3520
9Anti-Infective AgentsPhase 2, Phase 3, Phase 121402
10
LactitolPhase 3, Phase 2, Phase 1332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
11ImmunoglobulinsPhase 3, Phase 2, Phase 16045
12AntibodiesPhase 3, Phase 2, Phase 16045
13Pharmaceutical SolutionsPhase 3, Phase 1, Phase 27793
14MF59 oil emulsionPhase 3, Phase 2, Phase 1101
15AgglutininsPhase 3, Phase 1, Phase 235
16Immunosuppressive AgentsPhase 312770
17Gastrointestinal AgentsPhase 3, Phase 1, Phase 28109
18CatharticsPhase 3520
19
Zanamivirapproved, investigationalPhase 2, Phase 123139110-80-860855
Synonyms:
(2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
139110-80-8
1a4g
2qwe
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
4-Guanidino-NeueAc2en
4-Guanidino-neu5ac2en
5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
AC1L1U2A
BIDD:GT0349
C08095
CHEBI:50663
CHEMBL222813
CID60855
 
CPD000469215
D00902
DB00558
GANA
GG-167
GG167
GNA
GR-121167X
GR121167X
MODIFIED SIALIC ACID
Modified sialic acid
Relenza
Relenza (TN)
SAM001246788
ZANAMIVIR
ZMR
Zanamavir
Zanamivir (USAN/INN)
Zanamivir hydrate
zanamivir
20
AmantadineapprovedPhase 267768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
21
DopamineapprovedPhase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
22Anti-Ulcer AgentsPhase 1, Phase 21767
23AntacidsPhase 1, Phase 21767
24Adjuvants, ImmunologicPhase 2, Phase 12484
25Aluminum sulfatePhase 287
26Dopamine AgentsPhase 23759
27Peripheral Nervous System AgentsPhase 222776
28gamma-GlobulinsPhase 2317
29Neurotransmitter AgentsPhase 217734
30Antiparkinson AgentsPhase 21527
31Rho(D) Immune GlobulinPhase 2317
32Immunoglobulins, IntravenousPhase 2324
33AnalgesicsPhase 211287
34Analgesics, Non-NarcoticPhase 26260
35
ProbenecidapprovedPhase 12757-66-94911
Synonyms:
4-((Dipropylamino)sulfonyl)benzoic acid
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(Di-n-propylsulfamoyl)benzoesaeure
4-(Dipropylsulfamoyl)benzoic acid
4-(N,N-Dipropylsulfamoyl)benzoesaeure
4-[(dipropylamino)sulfonyl]benzoic acid
57-66-9
AB00052080
AC-2023
AC1L1J86
AC1Q2XQM
AC1Q2XQN
AI3-50078
AKOS000165123
Apurina
BIDD:GT0626
BIDD:PXR0092
BPBio1_000643
BRD-K95237249-001-05-9
BRN 2815775
BSPBio_000583
BSPBio_002227
Bencid
Benecid
Benemid
Benemid (TN)
Benemide
Benuryl
Biokanol Brand of Probenecid
C07372
C13H19NO4S
CAS-57-66-9
CCRIS 3643
CHEBI:177474
CHEMBL897
CID4911
CPD000058280
Col-BENEMID
Col-Probenecid
ColBenemid (co mponent of)
ColBenemid (component of)
Colbenemid
D00475
D011339
DB01032
DivK1c_000056
EINECS 200-344-3
HMS1569N05
HMS1920J22
HMS2092C03
HMS500C18
HSDB 3387
I01-1905
ICN Brand of Probenecid
IDI1_000056
IDIS Brand of Probenecid
KBio1_000056
KBio2_001314
KBio2_003882
KBio2_006450
KBio3_001727
KBioGR_000971
KBioSS_001314
LS-33
MLS000028496
MLS001076472
Major Brand of Probenecid
Martec Brand of Probenecid
Merck Brand of Probenecid
MolPort-000-145-935
NCGC00016251-01
NCGC00016251-02
NCGC00023829-03
 
NCGC00023829-04
NCGC00023829-05
NCGC00023829-06
NCI-C56097
NINDS_000056
NSC 18786
NSC18786
Ophthalmic Brand of Probenecid
Oprea1_416955
P-(Dipropylsulfamoyl)benzoic acid
P8761_SIGMA
Panuric
Parabenem
Parmed Brand of Probenecid
Polycillin-BRB
Polycillin-PRB
Polycillin-PRB (component of)
Prestwick0_000542
Prestwick1_000542
Prestwick2_000542
Prestwick3_000542
Prestwick_809
Pro-Cid
Probalan
Probampacin
Probecid
Proben
Proben-C
Probenecid (JP15/USP/INN)
Probenecid Acid
Probenecid Major Brand
Probenecid Martec Brand
Probenecid Parmed Brand
Probenecid Weimer
Probenecid Zenith Brand
Probenecid [INN:BAN:JAN]
Probenecid acid
Probenecida
Probenecida [INN-Spanish]
Probenecide
Probenecide [INN-French]
Probenecidum
Probenecidum [INN-Latin]
Probenemid
Probenicid
Probenid
Probexin
Prolongine
Robenecid
SAM002554923
SBB028597
SMR000058280
SPBio_001327
SPBio_002504
SPECTRUM1500502
Spectrum2_001294
Spectrum3_000554
Spectrum4_000486
Spectrum5_001419
Spectrum_000834
Sulprin
Synergid R
Tubophan
UNII-PO572Z7917
Uricosid
Urocid
Valdecasas Brand of Probenecid
WLN: QVR DSWN3&3
Zenith Brand of Probenecid
p-(Dipropylsulfamoyl)benzoic acid
p-(Dipropylsulfamyl)benzoic acid
p-[Dipropylsulfamoyl]benzoic acid
probenecid
probenicid
36
Peramivirapproved, investigationalPhase 115229614-55-5, 330600-85-6151164
Synonyms:
(1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
1A5BB290
229614-55-5
229614-56-6
3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid
3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
330600-85-6
AC1L45SI
AC1L4BWX
BCX 1812
BCX-1812
BCX1812
 
BCZ
CHEBI:292932
CHEBI:41095
CHEMBL139367
CHEMBL332608
CID151164
CID154234
PeramiFlu
Peramivir
RWJ 270201
RWJ-270201
RWJ270201
Rapiacta
S-021812
UNII-QW7Y7ZR15U
37
Inulinapproved, nutraceuticalPhase 11029005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
38Renal AgentsPhase 1732
39Anti-Bacterial AgentsPhase 110884
40Antibiotics, AntitubercularPhase 16972
41Antirheumatic AgentsPhase 110627

Interventional clinical trials:

(show top 50)    (show all 210)
idNameStatusNCT IDPhase
1Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult PatientsUnknown statusNCT01017172Phase 4
2Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldCompletedNCT01730378Phase 4
3The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza VaccineCompletedNCT02269852Phase 4
4H5N1 Vaccine Study in Japanese AdultsCompletedNCT01382329Phase 2, Phase 3
5Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of AgeCompletedNCT01310413Phase 3
6Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureCompletedNCT01788228Phase 3
7Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly SubjectsCompletedNCT00434733Phase 3
8Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsCompletedNCT00711295Phase 3
9Japanese Pediatric H5N1 Vaccine StudyCompletedNCT01911754Phase 3
10H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and OlderCompletedNCT01774032Phase 3
11Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00462215Phase 3
12Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four DifferentCompletedNCT00848029Phase 3
13Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 3
14Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00319098Phase 3
15Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersCompletedNCT01987011Phase 3
16Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00616928Phase 3
17Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly SubjectsCompletedNCT00841763Phase 3
18A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01379937Phase 3
19Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsCompletedNCT02091908Phase 3
20Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination SchedulesCompletedNCT00652743Phase 3
21Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic DiseasesCompletedNCT00519064Phase 3
22A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 MonthsCompletedNCT01000311Phase 3
23Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3
24A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeActive, not recruitingNCT02839330Phase 3
25A Safety and Immunogenicity Study of IVACFLU-A/H5N1Not yet recruitingNCT02612909Phase 2, Phase 3
26Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under OneWithdrawnNCT01546935Phase 2, Phase 3
27Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 VirusesUnknown statusNCT00417560Phase 1, Phase 2
28Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy AdultsUnknown statusNCT01640691Phase 1, Phase 2
29Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus InfectionUnknown statusNCT02095444Phase 1, Phase 2
30Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT01776541Phase 2
31Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 2
32Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2
33Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza VaccineCompletedNCT00561184Phase 2
34H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
35Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2
36Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsCompletedNCT00537524Phase 2
37Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly SubjectsCompletedNCT00914771Phase 2
38Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2
39H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1, Phase 2
40H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 2
41Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedNCT01195038Phase 2
42Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1, Phase 2
43Safety, Reactogenicity and Immunogenicity of an H5N1 VLPCompletedNCT00519389Phase 1, Phase 2
44A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1, Phase 2
45H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
46A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64CompletedNCT00695669Phase 2
47H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
48Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsCompletedNCT00382187Phase 2
49Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in AdultsCompletedNCT01416571Phase 2
50Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedNCT00980447Phase 2

Search NIH Clinical Center for Avian Influenza


Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

About this section

Anatomical Context for Avian Influenza

About this section

MalaCards organs/tissues related to Avian Influenza:

36
Testes, Lung, B cells, T cells, Trachea, Myeloid, Brain

FMA organs/tissues related to Avian Influenza:

17
Respiratory tract of humans

Publications for Avian Influenza

About this section

Articles related to Avian Influenza:

(show top 50)    (show all 712)
idTitleAuthorsYear
1
Single PA mutation as a high yield determinant of avian influenza vaccines. (28084423)
2017
2
Novel variants of clade 2.3.2.1 H5N1 highly pathogenic avian influenza virus in migratory waterfowl of Hongze Lake. (28062014)
2017
3
H9N2 avian influenza virus enhances the immune responses of BMDCs by down-regulating miR29c. (28063705)
2017
4
Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. (28079520)
2017
5
Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models. (28061848)
2017
6
Quantifying predictors for the spatial diffusion of avian influenza virus in China. (28086751)
2017
7
Proteome Response of Chicken Embryo Fibroblast Cells to Recombinant H5N1 Avian Influenza Viruses with Different Neuraminidase Stalk Lengths. (28079188)
2017
8
Novel real-time PCR-based patho- and phylotyping of potentially zoonotic avian influenza A subtype H5 viruses at risk of incursion into Europe in 2017. (28084214)
2017
9
Estimating Risks of Inapparent Avian Exposure for Human Infection: Avian Influenza Virus A (H7N9) in Zhejiang Province, China. (28054599)
2017
10
OIE avian influenza portal. (28062760)
2017
11
Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy. (28077631)
2017
12
Experimental infection of mandarin duck with highly pathogenic avian influenza A (H5N8 and H5N1) viruses. (28062008)
2017
13
Application of Species Distribution Modeling for Avian Influenza surveillance in the United States considering the North America Migratory Flyways. (27624404)
2016
14
Highly Pathogenic Eurasian H5N8 Avian Influenza Outbreaks in Two Commercial Poultry Flocks in California. (27610732)
2016
15
Amino acid substitutions involved in the adaptation of a novel highly pathogenic H5N2 avian influenza virus in mice. (27663652)
2016
16
Unexpected Inter-farm Transmission Dynamics During a Highly Pathogenic Avian Influenza Epidemic. (27147741)
2016
17
Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus. (27640441)
2016
18
Surveillance of Avian Influenza Virus in Aquatic Birds on the Brazilian Amazon Coast. (27645753)
2016
19
Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9). (27131142)
2016
20
Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation. (28012921)
2016
21
The avian influenza H9N2 at avian-human interface: A possible risk for the future pandemics. (28083072)
2016
22
Continuing Reassortant of H5N6 Subtype Highly Pathogenic Avian Influenza Virus in Guangdong. (27148209)
2016
23
An evaluation of biosecurity compliance levels and assessment of associated risk factors for Highly Pathogenic Avian Influenza H5N1 infection of Live-Bird-Markets, Nigeria and Egypt. (27603430)
2016
24
Susceptibility of primary chicken intestinal epithelial cells for low pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus. (27596739)
2016
25
High antiviral effects of hibiscus tea extract on the H5 subtypes of low and highly pathogenic avian influenza viruses. (27193820)
2016
26
Identification of Epitopes for Neutralizing Antibodies Against H10N8 Avian Influenza Virus Hemagglutinin. (27594152)
2016
27
Genetic characterization and phylogenic analysis of H5N1 avian influenza virus detected in peafowl in Kirkuk province, Iraq. (28036106)
2016
28
Characterization and Sequencing of an H6N6 Avian Influenza Virus Isolated from Sansui Sheldrake Ducks in Guizhou, Southwestern China. (27174267)
2016
29
Investigation into the Airborne Dissemination of H5N2 Highly Pathogenic Avian Influenza Virus During the 2015 Spring Outbreaks in the Midwestern United States. (27610723)
2016
30
Multiple introductions of a reassortant H5N1 avian influenza virus of clade 2.3.2.1c with PB2 gene of H9N2 subtype into Indian poultry. (27174088)
2016
31
Highly Pathogenic Avian Influenza A(H5N1) Virus among Poultry, Ghana, 2015. (27584829)
2016
32
Pre-immune state induced by chicken interferon gamma inhibits the replication of H1N1 human and H9N2 avian influenza viruses in chicken embryo fibroblasts. (27121613)
2016
33
Changes in adaptation of H5N2 highly pathogenic avian influenza H5 clade 2.3.4.4 viruses in chickens and mallards. (27632565)
2016
34
Avian influenza virus in pregnancy. (27187752)
2016
35
Isolation of H5N6, H7N9 and H9N2 avian influenza A viruses from air sampled at live poultry markets in China, 2014 and 2015. (27608369)
2016
36
Call for vigilance as H5N8 avian influenza confirmed in Lincolnshire. (28008104)
2016
37
Interventions in live poultry markets for the control of avian influenza: a systematic review. (27213177)
2016
38
Composition of the Hemagglutinin Polybasic Proteolytic Cleavage Motif Mediates Variable Virulence of H7N7 Avian Influenza Viruses. (28004772)
2016
39
Pathogenicity, Transmission and Antigenic Variation of H5N1 Highly Pathogenic Avian Influenza Viruses. (27199961)
2016
40
Isolation and molecular characterization of reassortant H11N3 subtype avian influenza viruses isolated from domestic ducks in Zhejiang Province in China. (27142079)
2016
41
The Dynamics of Avian Influenza: Individual-Based Model with Intervention Strategies in Traditional Trade Networks in Phitsanulok Province, Thailand. (27110273)
2016
42
Enhanced virulence of clade 2.3.2.1 highly pathogenic avian influenza A H5N1 viruses in ferrets. (28038412)
2016
43
Corrigendum: Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. (27648005)
2016
44
Characteristics of two highly pathogenic avian influenza H5N8 viruses with different pathogenicity in mice. (27589977)
2016
45
Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge. (27102817)
2016
46
Yeast Surface-Displayed H5N1 Avian Influenza Vaccines. (28078309)
2016
47
Vaccination with Astragalus and Ginseng Polysaccharides Improves Immune Response of Chickens against H5N1 Avian Influenza Virus. (27597953)
2016
48
Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India. (28004018)
2016
49
Isolation and genetic characterization of novel reassortant H6N6 subtype avian influenza viruses isolated from chickens in eastern China. (27101069)
2016
50
Surveillance, epidemiological, and virological detection of highly pathogenic H5N1 avian influenza viruses in duck and poultry from Bangladesh. (27599930)
2016

Variations for Avian Influenza

About this section

Expression for genes affiliated with Avian Influenza

About this section
Search GEO for disease gene expression data for Avian Influenza.

Pathways for genes affiliated with Avian Influenza

About this section

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.7FURIN, PCSK5, PCSK6
2
Show member pathways
9.6DDX58, IRF7, STAT2
3
Show member pathways
9.2CXCL10, DDX58, IFNA1, IRF7
4
Show member pathways
9.1DDX58, IFNA1, IRF7, STAT2
5
Show member pathways
9.1IFNA1, IRF7, STAT2, TNF
6
Show member pathways
8.9CXCL10, DDX58, IFNA1, IRF7, TNF
78.8DDX58, IFNA1, IRF7, STAT2, TNF
8
Show member pathways
8.6CXCL10, DDX58, IFNA1, IRF7, STAT2, TNF
98.6CXCL10, DDX58, IFNA1, IRF7, STAT2, TNF
10
Show member pathways
7.5CXCL10, DDX58, FURIN, IFNA1, IRF7, STAT2

GO Terms for genes affiliated with Avian Influenza

About this section

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi lumenGO:00057969.7FURIN, PCSK5, PCSK6
2extracellular spaceGO:00056158.8CXCL10, FURIN, IFNA1, PCSK5, PCSK6, SFTPD

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1nerve growth factor productionGO:003290210.6FURIN, PCSK6
2positive regulation of interferon-alpha productionGO:003272710.6DDX58, IRF7
3positive regulation of interferon-beta productionGO:003272810.6DDX58, IRF7
4peptide biosynthetic processGO:004304310.6FURIN, PCSK5
5embryonic digestive tract developmentGO:004856610.6PCSK5, TNF
6positive regulation of membrane protein ectodomain proteolysisGO:005104410.6FURIN, TNF
7negative regulation of myoblast differentiationGO:004566210.6CXCL10, TNF
8positive regulation of interleukin-8 productionGO:003275710.6DDX58, TNF
9secretion by cellGO:003294010.5FURIN, PCSK6
10signal peptide processingGO:000646510.5FURIN, PCSK5
11nerve growth factor processingGO:003245510.4FURIN, PCSK5, PCSK6
12peptide hormone processingGO:001648610.3FURIN, PCSK5, PCSK6
13protein processingGO:001648510.3FURIN, PCSK5, PCSK6
14regulation of type I interferon-mediated signaling pathwayGO:006033810.2IFNA1, STAT2
15response to virusGO:000961510.0CXCL10, DDX58, IRF7, TNF
16viral life cycleGO:001905810.0FURIN, PCSK5
17type I interferon signaling pathwayGO:00603379.7IFNA1, IRF7, STAT2
18innate immune responseGO:00450879.7DDX58, IFNA1, IRF7, SFTPD

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nerve growth factor bindingGO:004840610.6FURIN, PCSK6
2endopeptidase activityGO:000417510.3FURIN, PCSK5, PCSK6
3serine-type endopeptidase activityGO:00042528.3FURIN, PCSK5, PCSK6, TMPRSS11A, TMPRSS13

Sources for Avian Influenza

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet